Biotech company Biogen lowered its full-year profit forecast, citing higher costs related to its purchase of drug maker Reata Pharmaceuticals as well as the launch of its Alzheimer's drug.
Stocks were mixed at the open but Wall Street was heading for a losing week as investors digested the hints that the Federal Reserve could raise rates before the end of the year.